Development of a new scoring system for predicting recurrent thrombosis in patients with antiphospholipid syndrome.

IF 2.8 4区 医学 Q3 RHEUMATOLOGY
Oh Chan Kwon, Jang Woo Ha, Min-Chan Park, Yong-Beom Park, Sang-Won Lee
{"title":"Development of a new scoring system for predicting recurrent thrombosis in patients with antiphospholipid syndrome.","authors":"Oh Chan Kwon, Jang Woo Ha, Min-Chan Park, Yong-Beom Park, Sang-Won Lee","doi":"10.1186/s42358-025-00476-1","DOIUrl":null,"url":null,"abstract":"<p><p>BACKGROUND: This study aimed to develop a new scoring system for predicting recurrent thrombosis in patients with antiphospholipid syndrome (APS). METHODS: This was a retrospective multicentre cohort study. Patients with APS were followed up from APS diagnosis to either recurrent thrombosis or their last follow-up date, whichever came first. A multivariable logistic regression analysis with a backward elimination was used to develop a new scoring system, incorporating conventional cardiovascular risk factors and antiphospholipid antibody (aPL) profile as covariates. Each covariate remaining in the final step was multiplied by its β coefficient, rounded to the nearest integer, and then summed. A multivariable Cox proportional hazard model, adjusted for medication use, assessed the association between the new scoring system and recurrent thrombosis risk. The accuracy of the new scoring system in predicting recurrent thrombosis was evaluated by estimating the area under the curve (AUC) and comparing it with the adjusted global APS score (aGAPSS). RESULTS: A total of 126 patients with APS were included. The median age of the cohort was 40 (interquartile range: 31–55) years and 49.2% were women. Hypertension, type 2 diabetes mellitus (T2DM), and dyslipidaemia were present in 20.6%, 18.3%, and 54.0% of the patients, respectively. 26.2% were current smokers and 23.8% had concomitant systemic lupus erythematosus. Lupus anticoagulant (LA), anti-β2 glycoprotein I (anti-β2GPI) IgG, anti-β2GPI IgM, anti-cardiolipin (aCL) IgG, and aCL IgM were positive in 76.2%, 27.0%, 11.9%, 27.0%, and 6.3% of the patients, respectively. During a median follow-up duration of 41.5 (interquartile range: 21.4–72.0) months, thrombosis recurred in 9 (7.1%) patients. Multivariable logistic regression analysis revealed the following scoring system: modified diabetes global APS score (mdGAPSS) = 1*T2DM + 2*LA + 1*anti-β2GPI. Multivariable Cox proportional hazard model showed that a higher score was significantly associated with an increased risk of recurrent thrombosis (adjusted hazard ratio 2.911, 95% confidence interval 1.090–7.770, p = 0.033). The AUC was higher using the mdGAPSS (AUC = 0.706) than the aGAPSS (AUC = 0.553). CONCLUSIONS: Compared to the aGAPSS, the mdGAPSS—comprising T2DM, LA, and anti-β2GPI—demonstrated a greater accuracy in predicting recurrent thrombosis in patients with APS. </p>","PeriodicalId":48634,"journal":{"name":"Advances in Rheumatology","volume":"65 1","pages":"40"},"PeriodicalIF":2.8000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13488639/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s42358-025-00476-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND: This study aimed to develop a new scoring system for predicting recurrent thrombosis in patients with antiphospholipid syndrome (APS). METHODS: This was a retrospective multicentre cohort study. Patients with APS were followed up from APS diagnosis to either recurrent thrombosis or their last follow-up date, whichever came first. A multivariable logistic regression analysis with a backward elimination was used to develop a new scoring system, incorporating conventional cardiovascular risk factors and antiphospholipid antibody (aPL) profile as covariates. Each covariate remaining in the final step was multiplied by its β coefficient, rounded to the nearest integer, and then summed. A multivariable Cox proportional hazard model, adjusted for medication use, assessed the association between the new scoring system and recurrent thrombosis risk. The accuracy of the new scoring system in predicting recurrent thrombosis was evaluated by estimating the area under the curve (AUC) and comparing it with the adjusted global APS score (aGAPSS). RESULTS: A total of 126 patients with APS were included. The median age of the cohort was 40 (interquartile range: 31–55) years and 49.2% were women. Hypertension, type 2 diabetes mellitus (T2DM), and dyslipidaemia were present in 20.6%, 18.3%, and 54.0% of the patients, respectively. 26.2% were current smokers and 23.8% had concomitant systemic lupus erythematosus. Lupus anticoagulant (LA), anti-β2 glycoprotein I (anti-β2GPI) IgG, anti-β2GPI IgM, anti-cardiolipin (aCL) IgG, and aCL IgM were positive in 76.2%, 27.0%, 11.9%, 27.0%, and 6.3% of the patients, respectively. During a median follow-up duration of 41.5 (interquartile range: 21.4–72.0) months, thrombosis recurred in 9 (7.1%) patients. Multivariable logistic regression analysis revealed the following scoring system: modified diabetes global APS score (mdGAPSS) = 1*T2DM + 2*LA + 1*anti-β2GPI. Multivariable Cox proportional hazard model showed that a higher score was significantly associated with an increased risk of recurrent thrombosis (adjusted hazard ratio 2.911, 95% confidence interval 1.090–7.770, p = 0.033). The AUC was higher using the mdGAPSS (AUC = 0.706) than the aGAPSS (AUC = 0.553). CONCLUSIONS: Compared to the aGAPSS, the mdGAPSS—comprising T2DM, LA, and anti-β2GPI—demonstrated a greater accuracy in predicting recurrent thrombosis in patients with APS.

一种预测抗磷脂综合征患者复发性血栓形成的新评分系统的开发。
背景:本研究旨在开发一种新的评分系统来预测抗磷脂综合征(APS)患者血栓复发。方法:这是一项回顾性多中心队列研究。对APS患者进行随访,从APS诊断到血栓复发或最后一次随访日期,以先到者为准。以传统心血管危险因素和抗磷脂抗体(aPL)谱为协变量,采用反向消除的多变量logistic回归分析建立新的评分系统。最后一步剩余的每个协变量乘以它的β系数,四舍五入到最接近的整数,然后求和。一个多变量Cox比例风险模型,经药物使用调整后,评估了新的评分系统与血栓复发风险之间的关系。通过估算曲线下面积(AUC)并将其与调整后的APS评分(aGAPSS)进行比较,评估新评分系统预测血栓复发的准确性。结果:共纳入126例APS患者。队列的中位年龄为40岁(四分位数范围:31-55岁),49.2%为女性。高血压、2型糖尿病(T2DM)和血脂异常分别占20.6%、18.3%和54.0%。26.2%为吸烟者,23.8%患有系统性红斑狼疮。狼疮抗凝血剂(LA)、抗β2糖蛋白I(抗β 2gpi) IgG、抗β 2gpi IgM、抗心磷脂(aCL) IgG和aCL IgM阳性率分别为76.2%、27.0%、11.9%、27.0%和6.3%。中位随访时间为41.5个月(四分位数间距:21.4-72.0个月),9例(7.1%)患者血栓复发。多变量logistic回归分析得出如下评分体系:改良糖尿病全球APS评分(mdGAPSS) = 1*T2DM + 2*LA + 1*抗β 2gpi。多变量Cox比例风险模型显示,评分越高,血栓再发风险越高(校正风险比2.911,95%可信区间1.090 ~ 7.770,p = 0.033)。mdGAPSS的AUC (AUC = 0.706)高于aGAPSS (AUC = 0.553)。结论:与aGAPSS相比,mdgapss——包括T2DM、LA和抗β 2gpi——在预测APS患者血栓复发方面表现出更高的准确性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Advances in Rheumatology
Advances in Rheumatology Medicine-Rheumatology
CiteScore
4.00
自引率
4.30%
发文量
41
审稿时长
53 weeks
期刊介绍: Formerly named Revista Brasileira de Reumatologia, the journal is celebrating its 60th year of publication. Advances in Rheumatology is an international, open access journal publishing pre-clinical, translational and clinical studies on all aspects of paediatric and adult rheumatic diseases, including degenerative, inflammatory and autoimmune conditions. The journal is the official publication of the Brazilian Society of Rheumatology and welcomes original research (including systematic reviews and meta-analyses), literature reviews, guidelines and letters arising from published material.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书